Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.

Detaljer

Författare
  • Pia Burman
  • Britt Edén-Engström
  • Bertil Ekman
  • F Anders Karlsson
  • Erik Schwarcz
  • Jeanette Wahlberg
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Endokrinologi och diabetes
Originalspråkengelska
Sidor (från-till)17-24
TidskriftEuropean Journal of Endocrinology
Volym174
Utgivningsnummer1
StatusPublished - 2016
PublikationskategoriForskning
Peer review utfördJa